全文获取类型
收费全文 | 148781篇 |
免费 | 12533篇 |
国内免费 | 6645篇 |
专业分类
耳鼻咽喉 | 1142篇 |
儿科学 | 3325篇 |
妇产科学 | 2202篇 |
基础医学 | 25009篇 |
口腔科学 | 2857篇 |
临床医学 | 13094篇 |
内科学 | 20540篇 |
皮肤病学 | 2144篇 |
神经病学 | 19662篇 |
特种医学 | 3257篇 |
外国民族医学 | 28篇 |
外科学 | 15848篇 |
综合类 | 18193篇 |
现状与发展 | 25篇 |
一般理论 | 2篇 |
预防医学 | 4676篇 |
眼科学 | 1695篇 |
药学 | 18593篇 |
23篇 | |
中国医学 | 3362篇 |
肿瘤学 | 12282篇 |
出版年
2024年 | 192篇 |
2023年 | 2067篇 |
2022年 | 2738篇 |
2021年 | 5114篇 |
2020年 | 4750篇 |
2019年 | 4912篇 |
2018年 | 5059篇 |
2017年 | 5052篇 |
2016年 | 5012篇 |
2015年 | 5855篇 |
2014年 | 9562篇 |
2013年 | 11894篇 |
2012年 | 8517篇 |
2011年 | 10033篇 |
2010年 | 8394篇 |
2009年 | 8065篇 |
2008年 | 8263篇 |
2007年 | 7847篇 |
2006年 | 6870篇 |
2005年 | 6097篇 |
2004年 | 5384篇 |
2003年 | 4715篇 |
2002年 | 3685篇 |
2001年 | 3155篇 |
2000年 | 2677篇 |
1999年 | 2296篇 |
1998年 | 2283篇 |
1997年 | 2143篇 |
1996年 | 1873篇 |
1995年 | 1570篇 |
1994年 | 1400篇 |
1993年 | 1205篇 |
1992年 | 980篇 |
1991年 | 900篇 |
1990年 | 749篇 |
1989年 | 653篇 |
1988年 | 549篇 |
1987年 | 518篇 |
1986年 | 567篇 |
1985年 | 766篇 |
1984年 | 720篇 |
1983年 | 480篇 |
1982年 | 549篇 |
1981年 | 483篇 |
1980年 | 398篇 |
1979年 | 247篇 |
1978年 | 182篇 |
1977年 | 163篇 |
1976年 | 121篇 |
1975年 | 88篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
目的:通过文献计量学分析方法,阐述并分析肺癌靶向治疗的研究热点与趋势。方法:文章检索了万方数据库、Web of Science、SooPAT(中国专利)数据库近10年来国内外肺癌靶向治疗的相关文献,以文献计量学方法,分析并归类了肺癌靶向治疗的研究热点与时效变迁的趋势。结果:在万方数据库3 744篇肺癌靶向治疗的中文文章中,发现作用于表皮生长因子受体基因突变位点的分子靶向药物-吉非替尼治疗非小细胞肺癌的研究是中国学者近10年的主要研究热点;在近10年Web of Science数据库中检索到的810篇英文文章及参考文献显示,西妥昔单抗、贝伐单抗、纳武单抗、吉非替尼、厄洛替尼和环唑替尼为这10年肺癌治疗领域靶向治疗的热点药物,而多种靶向药物的联合治疗、晚期非小细胞肺癌的靶向治疗效果和肺癌靶向治疗后的脑转移也成为近5年该领域的国际关注热点;中国肺癌靶向治疗领域的254项有权专利的分析显示,申报了专利的主要药物包括酸敏感的吉非替尼-氟硼二吡咯衍生物、顺铂抗肺癌主动靶向隐形类脂质体等。结论:文章采用文献计量学的量化分析技术,呈现出近10年肺癌靶向治疗已成为该领域专业研究者持续关注的热点,而如何选择正确的靶向药物或药物组合方案来解决肺癌治疗中的耐药性问题,同时最大程度地减少患者的不良反应,以延长患者的生存率,应是未来集中研究的方向。 相似文献
53.
目的:探讨超高CD34+采集的动员方案后序贯二次自体造血干细胞移植治疗难治性霍奇金淋巴瘤的疗效和安全性。方法:对1例经过多疗程一线、二线、新药、免疫等均难治的霍奇金淋巴瘤患者,予以IA+C方案化疗+G-CSF动员干细胞后采集出超高水平CD34+细胞,之后行自体造血干细胞移植,移植后获得完全缓解,再予序贯第二次自体造血干细胞移植进行巩固治疗。结果:总计输注单个核细胞数13.67×108/kg,CD34+细胞48.68×106/kg,第一次自体造血干细胞移植术后第7天造血功能恢复,复查全身PET-CT提示获得完全缓解,第二次自体造血干细胞移植术后第8天造血功能恢复,两次自体造血干细胞移植相关并发症均在可控范围内。结论:超高CD34+细胞采集的IA+C方案化疗+G-CSF动员可以让患者有机会进行多次自体造血干细胞移植,是临床动员的创新方案。对于难治性霍奇金淋巴瘤,序贯二次自体造血干细胞移植可达到更深层次缓解,且安全性较高,延长患者无疾病生存期及总生存期,为难治性霍奇金淋巴瘤治疗提供更多临床依据。 相似文献
54.
《Vaccine》2015,33(42):5613-5622
Recent phase IIb/III trials of a tetravalent live attenuated vaccine candidate revealed a need for improvement in the stimulation of protective immunity against diseases caused by dengue type 2 virus (DENV-2). Our attempts to develop particulate antigens for possibly supplementing live attenuated virus preparation involve generation and purification of recombinant DENV-2 virus-like particles (VLPs) derived from stably (prM+E)-expressing mosquito cells. Two VLP preparations generated with either negligible or enhanced prM cleavage exhibited different proportions of spherical particles and tubular particles of variable lengths. In BALB/c mice, VLPs were moderately immunogenic, requiring adjuvants for the induction of strong virus neutralizing antibody responses. VLPs with enhanced prM cleavage induced higher levels of neutralizing antibody than those without, but the stimulatory activity of both VLPs was similar in the presence of adjuvants. Comparison of EDIII-binding antibodies in mice following two adjuvanted doses of these VLPs revealed subtle differences in the stimulation of anti-EDIII binding antibodies. In cynomolgus macaques, VLPs with enhanced prM cleavage augmented strongly neutralizing antibody and EDIII-binding antibody responses in live attenuated virus-primed recipients, suggesting that these DENV-2 VLPs may be useful as the boosting antigen in prime-boost immunization. As the levels of neutralizing antibody induced in macaques with the prime-boost immunization were comparable to those infected with wild type virus, this virus-prime VLP-boost regimen may provide an immunization platform in which a need for robust neutralizing antibody response in the protection against DENV-2-associated illnesses could be tested. 相似文献
55.
《Biomaterials》2015
The aim of this paper is to present a method to produce macroporous thin membranes made of poly (ethyl acrylate-co-hydroxyethyl acrylate) copolymer network with varying cross-linking density for cell transplantation and prosthesis fabrication. The manufacture process is based on template techniques and anisotropic pore collapse. Pore collapse was produced by swelling the membrane in acetone and subsequently drying and changing the solvent by water to produce 100 microns thick porous membranes. These very thin membranes are porous enough to hold cells to be transplanted to the organism or to be colonized by ingrowth from neighboring tissues in the organism, and they present sufficient tearing stress to be sutured with surgical thread. The obtained pore morphology was observed by Scanning Electron Microscope, and confocal laser microscopy. Mechanical properties were characterized by stress–strain experiments in tension and tearing strength measurements. Morphology and mechanical properties were related to the different initial thickness of the scaffold and the cross-linking density of the polymer network. Seeding efficiency and proliferation of mesenchymal stem cells inside the pore structure were determined at 2 h, 1, 7, 14 and 21 days from seeding. 相似文献
56.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
57.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
58.
59.
60.